Aurinia Pharmaceuticals Inc.

Total Valuation

Aurinia Pharmaceuticals Inc. carries a market capitalization of 2.07B, placing it among publicly traded companies globally. Its enterprise value stands at 1.88B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Share Statistics

Aurinia Pharmaceuticals Inc. currently has 132.91M shares outstanding.

Valuation Ratios

Aurinia Pharmaceuticals Inc. trades at a trailing price-to-earnings ratio of 7.11. The price-to-sales ratio is 7.17, and the price-to-book ratio stands at 3.67.

Enterprise Valuation

On an enterprise value basis, Aurinia Pharmaceuticals Inc. trades at an EV/EBITDA multiple of 11.03 and an EV/FCF ratio of 10.23. The EV/Sales ratio of 6.02 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 12.45 provides insight into valuation relative to core operating earnings.

Financial Position

Aurinia Pharmaceuticals Inc. maintains a current ratio of 5.42, meaning it holds 5.4x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 10.43, indicating elevated leverage, while an interest coverage ratio of 41.43 demonstrates strong ability to service its debt obligations.

Financial Efficiency

Taxes

Over the trailing twelve months, Aurinia Pharmaceuticals Inc. has paid -153.75M in income taxes, reflecting an effective tax rate of 46.38.

Stock Price Statistics

Aurinia Pharmaceuticals Inc.'s stock has gained approximately 28.332% over the past 52 weeks. The 50-day moving average sits at 15.88, while the 200-day moving average is 15.49.

Income Statement

Over the trailing twelve months, Aurinia Pharmaceuticals Inc. generated 311.51M in revenue and converted that into 314.11M in net income, yielding earnings per share of 2.30. EBITDA reached 170.13M, while operating income came in at 150.75M.

Balance Sheet

Aurinia Pharmaceuticals Inc. holds 443.12M in cash and equivalents against 64.14M in total debt, resulting in a net debt position of -179.83M. Total book value stands at 614.86M, with working capital of 441.43M providing operational flexibility.

Cash Flow

Aurinia Pharmaceuticals Inc. produced 175.24M in operating cash flow over the past twelve months. After subtracting -176,000.00 in capital expenditures, free cash flow totaled 175.07M - equivalent to 1.33 per share.

Margins

Aurinia Pharmaceuticals Inc. operates with a gross margin of 90.36, reflecting its pricing power and cost economics. The operating margin of 48.39 and net profit margin of 100.84 provide insight into operational efficiency.

Dividends & Yields

Stock Splits

Aurinia Pharmaceuticals Inc.'s most recent stock split took place on October 23, 2013 with a 50:1 split ratio.

Scores

Aurinia Pharmaceuticals Inc. posts an Altman Z-Score of 8.30, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.